Avistone Biotechnology

Biomarkers

• EGFR exon 20 insertion2
• ROS1 fusion2
• EGFR exon 19 deletion / L858R1
• MET exon 14 skipping1
• NTRK1/2/3 fusion1

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

PLB1004 8vebreltinib 3sintilimab 1osimertinib 1

Upcoming readouts

Active phase 2 and 3 trials whose primary completion date falls in the next 12 months, according to the sponsor.

• 2026-10 Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC. Phase 2 · EGFR exon 19 deletion / L858R
• 2026-11 Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations Phase 2 · EGFR exon 19 deletion / L858R
• 2026-12 Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI Phase 1/2 · EGFR exon 19 deletion / L858R

Trials

12 of 13 trials shown

1. Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure

   Not yet recruiting Phase 3 Avistone Biotechnology Started 2025Primary completion 2027-12 NCT06970782

   vebreltinibPLB1004pemetrexedcarboplatincisplatin

   Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure

   EGFR exon 19 deletion / L858RNon-Small-Cell Lung Cancer

2. Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.

   Enrolling by invitation Phase 3 Avistone Biotechnology Started 2023Primary completion 2028-06 NCT06281964

   PLB1004pemetrexedcarboplatincisplatinsintilimab

   Tumor tissue is positive for EGFR Ex20ins as documentally confirmed by next-generation sequencing (NGS) testing or written confirma…

   EGFR exon 20 insertionNon-Small-Cell Lung Cancer

3. A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer

   Recruiting Phase 1/2 Avistone Biotechnology Started 2026Primary completion 2029-06 NCT07538804

   ANS02

   With documentation of EGFR alteration

   EGFR exon 19 deletion / L858RNon-Small Cell Lung Cancer

4. Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations

   Recruiting Phase 2 Avistone Biotechnology Started 2026Primary completion 2026-11 NCT07336732

   PLB1004

   …ublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations

   EGFR exon 19 deletion / L858RNon-Small-Cell Lung Cancer

5. Phase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positive

   Not yet recruiting Phase 1/2 Avistone Biotechnology Started 2025Primary completion 2028-03 NCT07063329

   PLB1004

   Patients with other EGFR mutations such as EGFR exon 20 insertion: They must have received platinum-based chemotherapy.

   EGFR exon 19 deletion / L858REGFR exon 20 insertionNSCLC (Non-small Cell Lung Cancer)

6. Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.

   Recruiting Phase 2 Avistone Biotechnology Started 2024Primary completion 2026-10 NCT06574347

   vebreltinibosimertinib FDA EUPLB1004

   Patients with previously untreated, EGFRm-positive (exon 19 deletion or L858R) and MET overexpression (IHC 3+) .

   EGFR exon 19 deletion / L858RNon-Small-Cell Lung Cancer

7. Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI

   Recruiting Phase 1/2 Avistone Biotechnology Started 2023Primary completion 2026-12 NCT06343064

   vebreltinibPLB1004

   EGFR mutations, including exon 19 deletion and exon 21 L858R.

   EGFR exon 19 deletion / L858RNon-Small-Cell Lung Cancer

8. A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)

   Active, not recruiting Phase 2 Avistone Biotechnology Started 2023Primary completion 2025-03 NCT06015503

   PLB1004

   Participants with EGFR ex20ins mutation.

   EGFR exon 20 insertionNSCLC (Non-small Cell Lung Cancer)

9. A Study to Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid Tumors

   Recruiting Phase 1 Avistone Biotechnology Started 2025Primary completion 2027-12 NCT06716138

   ANS03

   With documentation of ROS1 or NTRK alteration

   ROS1 fusionNTRK1/2/3 fusionLocally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration

10. A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer

    Recruiting Phase 1 Avistone Biotechnology Started 2024Primary completion 2028-02 NCT06046495

    PLB1004

    Have a documented EGFR mutation by a local test in tissue or plasma;

    EGFR exon 19 deletion / L858RNon-Small Cell Lung Cancer

11. A Study to Evaluate ANS014004 in Subjects With Locally Advanced or Metastatic Solid Tumors

    Active, not recruiting Phase 1 Avistone Biotechnology Started 2024Primary completion 2027-12 NCT06328439

    ANS014004

    Cohort 1: Subjects must have pathologically confirmed, diagnosed NSCLC with a MET exon 14 jump mutation, with or without other MET alterations, and prior treatment with an approve…

    MET exon 14 skippingLocally Advanced or Metastatic Solid Tumors

12. A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors

    Recruiting Phase 1 Avistone Biotechnology Started 2024Primary completion 2027-04 NCT06307795

    ANS014004

    With a pathogenetic MET alteration or ROS1 alteration or NTRK alternation

    ROS1 fusionLocally Advanced or Metastatic Solid Tumors

No trials match these filters.